CDK11B and neoplasm: The siCDK11 siRNA sequence used in this experiment has 3/19 mismatches comparing the human CDK11A and CDK11B genes with the homologous mouse CDK11B (Cdc2L1) sequence; human siCDK11 is thus not likely to knockdown mouse CDK11 expression by Argonaute 2/RISC-based mechanisms, and the RACE products detected most probably derive from the human xenograft tumor cells.